Subscribe
tupungato
tupungato / iStockphoto.com
14 November 2018Big Pharma

UK Supreme Court issues Warner-Lambert v Actavis ruling

The UK Supreme Court today dismissed Warner-Lambert’s appeal in its pregabalin patent dispute with Actavis, while clarifying the role of plausibility in the sufficiency of patent applications.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Analysis: Kymab’s ‘patent bargain’ clarification and why it matters
25 June 2020   Yesterday’s UK Supreme Court decision in Kymab v Regeneron is expected to have profound implications for innovative life sciences companies, according to lawyers.
Big Pharma
Warner-Lambert v Actavis ‘disappointing’ for innovators: lawyers
15 November 2018   The UK Supreme Court’s decision in Warner-Lambert v Actavis is disappointing for pharmaceutical innovators, and enforcing second medical use patents may now be more challenging, lawyers have told LSIPR.
Big Pharma
Pfizer secures six-month Lyrica extension in US
29 November 2018   The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Biotechnology
Analysis: Kymab’s ‘patent bargain’ clarification and why it matters
25 June 2020   Yesterday’s UK Supreme Court decision in Kymab v Regeneron is expected to have profound implications for innovative life sciences companies, according to lawyers.
Big Pharma
Warner-Lambert v Actavis ‘disappointing’ for innovators: lawyers
15 November 2018   The UK Supreme Court’s decision in Warner-Lambert v Actavis is disappointing for pharmaceutical innovators, and enforcing second medical use patents may now be more challenging, lawyers have told LSIPR.
Big Pharma
Pfizer secures six-month Lyrica extension in US
29 November 2018   The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.

More on this story

Biotechnology
Analysis: Kymab’s ‘patent bargain’ clarification and why it matters
25 June 2020   Yesterday’s UK Supreme Court decision in Kymab v Regeneron is expected to have profound implications for innovative life sciences companies, according to lawyers.
Big Pharma
Warner-Lambert v Actavis ‘disappointing’ for innovators: lawyers
15 November 2018   The UK Supreme Court’s decision in Warner-Lambert v Actavis is disappointing for pharmaceutical innovators, and enforcing second medical use patents may now be more challenging, lawyers have told LSIPR.
Big Pharma
Pfizer secures six-month Lyrica extension in US
29 November 2018   The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court